The essential BCAAs valine, leucine and isoleucine largely escape first-pass liver catabolism and remain available to peripheral organs. Metabolism of these BCAAs provides an important mechanism by which nitrogen moves throughout the body for the synthesis of nonessential amino acids 1 , whereas deregulation of BCAA catabolic pathways frequently results in neural dysfunction 2 . The first step in BCAA catabolism is a transfer of an α-amino group to α-ketoglutarate (α-KG) through the activity of cytosolic BCAT1 or mitochondrial BCAT2 isoenzymes, yielding glutamate and the respective branched-chain α-ketoacids 3,4 . Whereas BCAT2 expression is nearly ubiquitous, BCAT1 expression is restricted to a small number of tissues, including the brain 5-7 , where BCAAs serve as a major source of nitrogen for neurotransmitter glutamate synthesis 8 . After transamination, branched-chain α-ketoacids are further catabolized to acetyl coenzyme A (acetyl-CoA) and succinyl-CoA, which are subsequently oxidized in the tricarboxylic acid cycle (Fig. 1a) to provide macromolecule precursors and energy for mitochondrial ATP synthesis.
The essential BCAAs valine, leucine and isoleucine largely escape first-pass liver catabolism and remain available to peripheral organs. Metabolism of these BCAAs provides an important mechanism by which nitrogen moves throughout the body for the synthesis of nonessential amino acids 1 , whereas deregulation of BCAA catabolic pathways frequently results in neural dysfunction 2 . The first step in BCAA catabolism is a transfer of an α-amino group to α-ketoglutarate (α-KG) through the activity of cytosolic BCAT1 or mitochondrial BCAT2 isoenzymes, yielding glutamate and the respective branched-chain α-ketoacids 3, 4 . Whereas BCAT2 expression is nearly ubiquitous, BCAT1 expression is restricted to a small number of tissues, including the brain [5] [6] [7] , where BCAAs serve as a major source of nitrogen for neurotransmitter glutamate synthesis 8 . After transamination, branched-chain α-ketoacids are further catabolized to acetyl coenzyme A (acetyl-CoA) and succinyl-CoA, which are subsequently oxidized in the tricarboxylic acid cycle (Fig. 1a) to provide macromolecule precursors and energy for mitochondrial ATP synthesis.
A dependence on glutamine catabolism for cell growth is frequently observed in malignant cells 9 and has been intensively investigated in glioblastoma [10] [11] [12] [13] [14] . Under hypoxic conditions, glutamine can be metabolized to citrate and fatty acids through an isocitrate dehydrogenasedependent pathway [15] [16] [17] . Mutations in cytoplasmic IDH1 and, less frequently, mitochondrial IDH2 are present in a majority of gliomas ranked as grade 2 or 3 by the World Health Organization (WHO) and secondary glioblastomas but are rare in the more common primary glioblastomas [18] [19] [20] . IDH1 and IDH2 mutations have a central role in glioma pathogenesis 20, 21 and constitute a key classifier distinguishing two major glioma subgroups identified on the basis of RNA expression and DNA methylation patterns [22] [23] [24] [25] [26] [27] . Although IDH1 mutation status is a powerful prognostic factor that refines conventional diagnostic procedures for high-grade astrocytomas 28 , several studies have shown that tissue-specific knock in of mutant IDH (IDH mut ) is insufficient to induce tumors in mice 29, 30 , leaving the specific mechanisms by which IDH mutations contribute to tumor development poorly understood. Mutant IDH enzymes produce 2-hydroxyglutarate (2-HG) from α-KG, and depletion of α-KG, its competitive inhibition by 2-HG or both are believed to reduce the function of enzymes using α-KG 31, 32 . Inhibition of histone demethylases and the TET family of 5-methylcytosine hydroxylases [33] [34] [35] by 2-HG probably accounts for the widespread hypermethylation of gene promoters in IDH mut gliomas and leukemias 24, 33 .
A better understanding of how differences in tumor metabolism are connected to growth patterns and the clinical behaviors of IDH mut gliomas and gliomas with wild-type IDH1 and IDH2 (IDH wt ) is essential. In particular, it is important to know how IDH wt tumors fuel the rapid proliferation that accounts for the aggressive clinical phenotype of IDH wt glioblastomas. To address this issue, we analyzed transcriptional profiles generated during a previous study on astrocytic gliomas 26 with a special emphasis on detecting molecular signatures characteristic of IDH wt tumors.
RESULTS

BCAT1 overexpression in IDH wt glioblastomas
Prediction analysis of gene expression data 26 identified BCAT1 as the best classifier to distinguish primary glioblastoma from secondary glioblastoma, diffuse astrocytoma and anaplastic astrocytoma ( Supplementary Tables 1 and 2 ). When classifying tumors on the basis of IDH mutation status, BCAT1 RNA expression levels were significantly higher in IDH wt gliomas relative to normal brain (P = 0.0051, two-tailed Student's t test) and IDH mut gliomas (P < 0.0001; Fig. 1b) . Compared to normal brain, BCAT1 RNA expression in IDH mut gliomas was downregulated (P = 0.0012). We did not observe comparable patterns of differential expression for BCAT2 (Fig. 1c) . By mapping gene expression data 26 onto the BCAA catabolic pathway using PathWave software 36 , we found that RNA expression levels for several other enzymes downstream of BCAT1 are also upregulated in IDH wt tumors relative to normal brain, indicating transcriptional activation of the entire pathway (Supplementary Fig. 1 ). Consistent with these RNA expression results, BCAT1 protein expression was high in IDH wt tumors but was essentially absent in IDH mut tumors regardless of the specific mutation in either IDH1 or IDH2 (Fig. 1d) .
We further confirmed a tight correlation in IDH1 or IDH2 mutation status and BCAT1 expression through immunohistochemical staining of sections from 81 primary human gliomas (Fig. 1e-j and Supplementary Fig. 2a) . We obtained independent confirmation through analysis of two published RNA expression data sets 37, 38 and a protein-level immunohistochemical analysis in an independent cohort of 210 gliomas ( Supplementary Fig. 2b-d) . These data clearly establish that high BCAT1 expression is a characteristic feature of IDH wt gliomas, which can be used to positively identify this tumor group in a diagnostic setting.
Substrate-dependent expression of BCAT1
We found that BCAT1 expression in glioblastoma cell lines is upregulated by hypoxia (Supplementary Fig. 3 ) and the addition of increasing concentrations of cell-permeable dimethyl-α-KG substrate to the culture medium (Fig. 2a) . Conversely, shRNA-mediated knockdown of IDH1, a major source of α-KG in the cytoplasm 39 , led to strong downregulation of BCAT1 expression (Fig. 2b) . This downregulation through IDH1 knockdown was almost completely reversed when dimethyl-α-KG was supplied in the culture medium (Fig. 2c) . The 2-HG produced by IDH mut in glioblastomas is a structural analog of α-KG that has been shown to inhibit α-KG-dependent enzymes 33, 35 . To determine whether 2-HG affects BCAT1 activity, we compared its inhibitory effect to those of α-ketoisocaproate (KIC) and α-KG in brain detergent extracts from Bcat2 knockout mice 40 , in which only Bcat1 activity is retained (Fig. 2d) . A 40-fold excess of α-KG to α-ketoisovalerate (KIV) and a tenfold molar excess of KIC to KIV inhibited Bcat1 activity by 65% and 85%, respectively. Using up to 10 mM 2-HG, which is equivalent to a 100-fold molar excess relative to KIV, we achieved a maximum inhibition of 13%, indicating that BCAT1 is largely insensitive to 2-HG. 1  2  13  12  11  10  9  8  7  6  5  4  3   BCAT1   Tubulin   sGBIV  R132H  sGBIV  R132H  AAIII  R132H  AII  R132C  AII  R132S  AOIII  R172K  AII  R172K  pGBIV  pGBIV  pGBIV  pGBIV To more directly test the effects of mutant IDH1 on BCAT1 expression, we used immortalized human astrocytes (IHAs) stably overexpressing either wild-type IDH1 (IHA wt ) or R132H mutant IDH1 (IHA mut ) 38 . Analysis of published gene expression data 38 revealed that BCAT1 is downregulated in IHA mut cells. We showed by western blot and quantitative RT-PCR (qRT-PCR) analyses that BCAT1 expression levels were 40% lower in IHA mut compared to IHA wt cells (Fig. 2e) , indicating that IDH1 mut expression suppresses BCAT1 expression in this cell line model. To determine whether BCAT1 expression can accelerate the growth rate of astrocytic cells, we ectopically overexpressed BCAT1 in IHA mut cells, resulting in a significant increase in proliferation rate (P = 0.0141, two-tailed Student's t test; Fig. 2f ). The substrate dependence of BCAT1 expression was maintained in IHA mut astrocytes (Fig. 2g) . In analyzing published data 38 , we could not detect any differences in BCAT1 promoter methylation between IHA mut and IHA wt cells (Fig. 2h) . This finding is consistent with our observation that IHA mut cells maintain an intermediate level of BCAT1 expression (Fig. 2e) .
BCAT1 promoter methylation and RNA expression in gliomas To better define BCAT1 expression patterns in IDH wt and IDH mut gliomas, we quantified transcript isoform expression in tumor samples from patients with glioma. Using RT-PCR and sequencing, we detected expression of three BCAT1 transcripts (T1, T4 and T6) coding for 386-, 398-and 385-residue proteins, respectively, in tumor and normal brain tissues (Supplementary Fig. 4) . These transcripts, which differ only in their first exons, originate from two alternative promoters (Fig. 3a) and correspond to the single protein band of 43 kDa identified using western blot analysis. Transcript-specific qRT-PCR identified T6 as the predominant transcript in primary gliomas (Fig. 3b) . Notably, expression of all BCAT1 transcripts (T1, T4 and T6) was significantly (P ≤ 0.001) higher in IDH wt compared to IDH mut tumors. Using sequence analysis of the BCAT1 promoter and coding regions from 20 gliomas, we found no nonsense or missense mutations that might affect BCAT1 expression levels in the patient tumors (Supplementary Table 3) .
We next explored the possibility that epigenetic silencing might account for BCAT1 transcript expression differences in tumors of patients with glioma. By analyzing patterns of BCAT1 promoter methylation with MassARRAY, we identified distinct methylation patterns in IDH wt and IDH mut (Fig. 3c) . Promoter 2 showed the typical pattern of IDH mut -dependent methylation, as it was hypermethylated in IDH mut tumors but was mostly unmethylated in IDH wt tumors and normal brain (Fig. 3d) . Hypermethylation in IDH mut tumors strongly correlated with BCAT1 downregulation. Notably, promoter 1 showed the opposite pattern, as it was hypermethylated in IDH wt tumors, particularly in the first three CpG dinucleotides of a small differentially methylated region (DMR) (Fig. 3e,f) . The average degree of methylation of the three CpGs correlated with BCAT1 transcript T1 expression in IDH wt tumors, supporting its functional relevance (Fig. 3g) . The observed CpG-specific methylation pattern suggests repressor binding to the unmethylated DMR, leading to the downregulation of the BCAT1 transcript T1 in IDH mut tumors. Consistent with HEY1 repressor activity, overexpression of HEY1 reduced transcript T1 expression, and chromatin immunoprecipitation analysis provided evidence for binding of HEY1 to the DMR in glioblastoma cells (Supplementary Fig. 5 ).
BCAT1 suppression reduces glutamate release and migration
To gain additional insights into the functional role of BCAT1 in glioblastomas, we treated cells from the U-87MG and U-373MG lines with is consistent with BCAT1 inhibition (Fig. 4a,b) . Glioblastomas release high concentrations of glutamate, leading to neuronal death by an excitotoxic mechanism 42 . Glutamate release was significantly reduced by inhibition of BCAT1 using gabapentin ( Fig. 4c) , Figure 3 indicating that BCAT1 is a major contributor to glutamate production through BCAA catabolism in IDH wt glioma. We analyzed the additional effects of BCAT1 suppression on amino acid metabolism by tandem mass spectrometry (MS/MS) after shRNA-mediated knockdown targeting all three BCAT1 transcripts (Supplementary Fig. 6 ). The observed changes in amino acid concentrations largely paralleled those reported in the plasma of Bcat2 knockout mice 40 . In Bcat2 knockout mice, inhibition of BCAA catabolism results in high concentrations of BCAAs and higher rates of protein synthesis in peripheral tissues through the mechanistic target of rapamycin (mTOR) signaling pathway and compensatory increased protein degradation (increased protein turnover). However, BCAT1 suppression did not cause increased phosphorylation of mTOR targets in glioma cells, perhaps because of the already high constitutive amounts of phosphorylation ( Supplementary Fig. 7 ). Hydroxyacyl-CoA dehydrogenase (HADH) is downstream of BCAT1 in the BCAA catabolic pathway and is also an essential component of fatty-acid catabolism (beta oxidation) in the mitochondria. We found both pathways to be upregulated in IDH wt tumors relative to normal brain (Supplementary Fig. 1 ). After BCAT1 knockdown in glioblastoma cell lines, we observed decreased HADH protein concentrations (Supplementary Fig. 6e ), providing additional evidence for the downregulation of the BCAA catabolic pathway, and concurrent accumulation of C4 short-chain fatty acids ( Supplementary  Fig. 6f) , consistent with obstruction of beta oxidation through HADH suppression 43 .
We observed that BCAT1 knockdown strongly affected cellular morphology, resulting in a rounded, less extended appearance (Fig. 4d,e) . To test whether these morphologies correlate with the ability of a tumor cell to invade adjacent tissues, we used a microchannel migration chip to simulate a three-dimensional environment (Fig. 4f) . After BCAT1 knockdown, a majority of U-87MG cells (55%) penetrated only short distances into the microchannels and were unable to deform to completely invade the microchannels, whereas a vast majority of control cells (78%) completely invaded the channels ( Fig. 4g and Supplementary Videos 1 and 2) .
Glioblastoma growth is BCAT1 dependent
To further assess the impact of BCAT1 function on tumor cell proliferation, we performed BCAT1 inhibition and knockdown experiments. We found a concentration-dependent ~56% reduction of proliferation, estimated based on 5-ethynyl-2′-deoxyuridine (EdU) incorporation, when we treated glioma cells with the inhibitor gabapentin (Fig. 5a) . Cell cycle analyses indicated that gabapentin treatment induced partial G1 arrest, as shown by an increased fraction of cells in the G1 phase along with concurrent decreases of the G2 and S fractions (Fig. 5b) . shRNA-mediated BCAT1 knockdown elicited similar effects, decreasing proliferation by 20-70% in all three cell lines (Fig. 5c ) and leading to G1 arrest and strong increases in cellular CDKN1B (also known as p27 KIP1 ) concentrations (Fig. 5d) . Notably, the degree of CDKN1B accumulation showed a positive correlation with the size of the G1 fraction (Fig. 5d) . Cell death, as indicated by the fraction of cells in the sub-G1 phase, remained below 5%, except in the case of Hs683 cells, which showed a moderate increase (Supplementary Table 4) . We observed comparable reductions of cell proliferation after BCAT1 knockdown in glioblastoma stem-like spheroid cultures in serum-free medium, although these cells showed a higher rate of apoptosis as determined by annexin V and 7-aminoactinomycin D (7-AAD) staining (Supplementary Fig. 8 ). Ectopic overexpression of BCAT1 in U-87MG BCAT1 knockdown cells significantly increased their proliferation rates and resulted in a partial rescue of the proliferation phenotype (Fig. 5e) . When we induced cell cycle arrest using means other than BCAT1 knockdown, the metabolic effects (Supplementary Fig. 9 ) did not mirror the effects observed in the BCAT1 knockdown cells, indicating that the previously Fig. 6a-f) were specific effects of BCAT1 suppression and not secondary effects of cell cycle arrest. We evaluated the effect of BCAT1 knockdown on tumor growth in vivo using intracerebral transplantation of U-87MG cells into CD-1 nude (nu/nu) mice (Fig. 6a-c) . Four weeks after transplantation of equal numbers of living cells, all six control mice transplanted with nontargeting shRNA-transduced cells but only one of six mice transplanted with BCAT1 shRNA-transduced cells showed neurologic symptoms such as lethargy or uncoordinated motor activities. H&E staining of mouse brain sections revealed large tumors in the mice transplanted with control cells (Fig. 6a) , whereas we found markedly smaller tumors in the mice transplanted with BCAT1 knockdown cells (Fig. 6b) . Quantitative analysis confirmed significant differences in tumor volume between the two groups ( Fig. 6c ; P = 0.0091). TUNEL assays did not detect DNA fragmentation in either control or BCAT1 knockdown tumors (Fig. 6d-f) , indicating that the growth of BCAT1 knockdown tumors in vivo is limited mostly by reduced proliferation rather than increased apoptosis rates. We obtained equivalent results when we used a Tet-inducible BCAT1 shRNA vector for BCAT1 knockdown and rescue in vitro and for monitoring reduced growth of xenograft tumors in which we induced BCAT1 knockdown 10 d after implantation (Supplementary Fig. 10 ). We isolated cells from the tumors of mice transplanted with BCAT1 shRNA-transduced cells that had not been treated with doxycycline and removed contaminating mouse cells by puromycin selection. Analysis of glutamate concentrations in the supernatant showed that after passage through the mouse, glioblastoma cells still excreted high amounts of glutamate (Fig. 6g) in a BCAT1-dependent manner (Fig. 6h) , strongly indicating that it was maintained in vivo.
DISCUSSION
Although it has been suggested that cancer cell proliferation is fueled primarily through the catabolism of glucose and glutamine 10, 44 , the results presented here provide evidence that IDH wt glioma cells require catabolism of BCAAs to sustain an aggressive growth phenotype. Notably, with the exception of a small number of earlier reports [45] [46] [47] [48] [49] and a recent in vitro metabolome analysis 50 , studies of BCAA metabolism have been restricted to nutrition science and glutamate neurotransmitter metabolism in the brain 1, 7, 8 . In the context of oncology research, the role of BCAT1 or BCAA catabolism in tumor growth has been largely overlooked.
The first crucial insight gleaned from our data is that although BCAT1 is clearly overexpressed in IDH wt gliomas, it is not expressed in the majority of IDH mut gliomas, implying a possible mechanistic link between these metabolic enzymes. IDH1 is a major source of α-KG 39 , which we showed to have a direct effect on the levels of BCAT1 expression. From this observation, one might be led to conclude that the observed BCAT1 downregulation in IDH mut cells could be explained in part by the depletion of α-KG in these cells. However, the partial reduction in the amounts of α-KG in IDH mut cells reported by others 51 is insufficient to explain the near total absence of BCAT1 expression we observed in IDH mut tumors. Furthermore, we experimentally excluded direct inhibition of BCAT1 enzymatic activity by the oncometabolite 2-HG, as has been described for epigenetic modifiers 32, 33, 35 . This is consistent with the observation that hydroxy acids are not BCAT substrates 52 , as they cannot form a Schiff base with the vitamin B6 cofactor. We did, however, observe extensive DNA hypermethylation within the main promoter region of BCAT1 in IDH mut tumors that was lacking in IDH wt tumors or normal brain. These correlative data suggest that BCAT1 is silenced at least in part through IDH1 mut -dependent DNA methylation.
In testing this hypothesis, we found that ectopic expression of IDH1 mut in immortalized astrocytes 38 resulted in a nearly 40% downregulation of BCAT1 expression, thus establishing a link between IDH1 mutation status and BCAT1 expression. However, it should be noted that IDH mut expression did not result in hypermethylation of the BCAT1 promoter in immortalized astrocytes, implying that DNA methylation might not have an initial regulatory role in BCAT1 suppression and might instead be a later event in BCAT1 silencing in IDH mut tumors.
In our study, suppression of BCAA catabolism by knockdown of BCAT1 resulted in reduced cell proliferation in vitro and in vivo. The mechanisms through which these metabolic changes affect glioblastoma cell proliferation are not known; however, we hypothesize that the blockage of BCAA and fatty acid catabolism (Supplementary Fig. 6g npg and tumor aggressiveness in breast cancer, where growth of estrogen receptor (ER) − and human epidermal growth factor receptor 2 (HER2) − tumors was shown to be dependent on upregulation of the serine synthesis pathway 53, 54 . Furthermore, higher expression of the glycine biosynthesis pathway has been found to be associated with greater mortality in patients with breast cancer 55 .
Although we have established the importance of BCAT1 for tumor growth, our finding that BCAT1 overexpression is a highly specific feature of IDH wt glioblastomas also makes BCAT1 a promising potential marker for diagnostic and prognostic assessment of gliomas, including the nearly 10% of IDH mut gliomas with mutations other than IDH1 R132H 56 that are not amenable to IDH1 R132H diagnostic staining 57 .
In addition, BCAT1 and BCAA metabolism could provide a basis for the development of new metabolism-based targeted approaches in glioma therapy. Blocking BCAA catabolism through selective inhibition of BCAT1 would, in addition to reducing tumor growth by interfering with tumor energy production and macromolecule synthesis, have the added benefit of reducing tumor glutamate excretion. This latter effect could potentially reduce neurotoxic damage in surrounding brain tissue 42 , alleviate tumor-associated epilepsy 58 in patients with brain tumors and perturb the tumor redox balance by inhibiting glutathione production 42 . We believe that the results of this study should greatly encourage the development of BCAT1 inhibitors for tumor therapy.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
ONLINE METHODS
RNA isolation and qRT-PCR. Total RNA was extracted using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen) according to the manufacturer's instructions. FirstChoice Human Brain Reference Total RNA from Ambion served as the normal brain RNA pool (n = 23 donors). Total RNA (500 ng) was reverse transcribed using random primers and superscript II (Invitrogen) according to the manufacturer's instructions. Each cDNA sample was analyzed in triplicate with the Applied Biosystems Prism 7900HT Fast Real-Time PCR System using Absolute SYBR Green ROX Mix (ABgene). The relative amount of specific mRNA was normalized to ARF1, B2M and TBP mRNA. Primer sequences are given in Supplementary Table 5 .
Western blot analysis. All experiments involving the use of human tissues were carried out in line with the guidelines of the institutional review board of the Medical Faculty at Heinrich Heine University Düsseldorf. Fresh frozen human tumor tissue samples and a non-neoplastic brain tissue sample were lysed in guanidine isothiocyanate solution (4 M) using an ULTRA-TURRAX (IKA) and subjected to cesium chloride (CsCl) ultracentrifugation. Diafiltration of the obtained protein fractions was performed using Amicon Ultra-0.5 centrifugal filter devices (Millipore; 3-kDa cutoff) essentially as described 59 . Total protein of cell lines was extracted using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen). Ten micrograms of protein was separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore). The membrane was blocked in blocking solution (5% BSA in TBS and 0.1% Tween 20) and incubated with primary antibodies overnight at 4 °C. Horseradish peroxidase (HRP)-conjugated secondary antibodies were incubated for 1 h at room temperature before chemiluminescent detection of protein (ECL kit, GE Healthcare).
The following antibodies were used: monoclonal mouse antibody to α-tubulin (1:2,000, clone DM1A, #T9026, Sigma-Aldrich), monoclonal mouse antibody to BCAT1 (1:2,000, ECA39, clone 51, #611270, BD Biosciences), monoclonal rat antiserum to IDH1 (1:2, generously provided by A. von Deimling), monoclonal mouse antibody to HADH (1:500, #H00003033-M01, Abnova), monoclonal rabbit antibody to CDKN1B (1:1,000, p27 Kip1 , #3686, Cell Signaling Technology), polyclonal rabbit antibody to p70 S6 kinase (1:1,000, #9202, Cell Signaling Technology), polyclonal rabbit antibody to phosphorylated p70 S6 kinase (Thr389) (1:1,000, #9205, Cell Signaling Technology), polyclonal rabbit antibody to 4E-BP1 (1:1,000, #9452, Cell Signaling Technology), polyclonal rabbit antibody to phosphorylated 4E-BP1 (Thr37/46) (1:1,000, #9459, Cell Signaling Technology), monoclonal rabbit antibody to phosphorylated S6 ribosomal protein (Ser235/236) (1:1,000, #4858, Cell Signaling Technology), HRP-conjugated antibody to rat IgG (1:10,000, generously provided by A. von Deimling), HRP-conjugated horse antibody to mouse IgG (1:5,000, #7076, Cell Signaling Technology) and HRP-conjugated goat antibody to rabbit IgG (1:2,000, #7074, Cell Signaling Technology).
Immunohistochemical staining. Tumor sections were deparaffinized using xylol and rehydrated in decreasing concentrations of ethanol. Antigen retrieval was performed by heating for 40 min in a steamer (90-95 °C) in 10 mM sodium citrate buffer (pH 6.0). Endogenous peroxidase was inactivated by incubating the tumor sections in 3% hydrogen peroxide for 10 min. Sections were incubated overnight with primary mouse monoclonal antibody to BCAT1 (ECA39, clone 51, #611270, BD Biosciences) diluted 1:500 or mouse antibody to human R132H IDH1 (generously provided by A. von Deimling) diluted 1:20 in Dako REAL antibody diluent (Dako). Staining for the detection of bound antibody was performed according to standard protocols using the EnVision detection system (peroxidase/DAB+, rabbit/ mouse) (Dako), and subsequent counterstaining was done using hematoxylin.
Mutation analysis. The BCAT1 gene (ENSG00000060982) was investigated for mutations in 20 tumors using the primers shown in Supplementary Table 5. All 11 exons and 1,000 bp of the promoter region of the BCAT1 transcript variant T1 (ENST00000261192) plus 1,700 bp of the promoter region of the transcript isoform T6 (ENST00000538118), including the two alternative exons (1b and 1c of the transcript isoforms T4 and T6), were amplified by PCR using GoTaq polymerase (Promega). PCR products were treated with ExoSAP (ExoSAP-IT, GE Healthcare) and sequenced in both directions using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
DNA methylation analysis. DNA methylation was analyzed by the MassARRAY technique as previously described 60 . Briefly, 500 ng of genomic DNA was chemically modified with sodium bisulfite using the EZ methylation Kit (Zymo Research) according to the manufacturer's instructions. The bisulfite-treated DNA was PCR amplified with primers generating four amplicons (A1-A4) from −990 bp to +612 bp around the transcription start site of the BCAT1 transcript T1 (ENST00000261192) and three amplicons (A5-A7) of the promoter of the BCAT1 transcripts T4 (ENST00000539282) and T6 (ENST00000538118) from −198 bp to +63 bp. The amplicons were transcribed by T7 polymerase, followed by thymidine-specific cleavage using RNase A. The digested fragments were quantified by mass spectrometry. The primer sequences are given in Supplementary Table 5 . DNA methylation standards (0%, 20%, 40%, 60%, 80% and 100% methylated genomic DNA) were used to confirm the unbiased amplification of the amplicons.
Cell culture. The human glioma cell lines U-87MG (HTB-14), LN-229 (CRL-2611), Hs683 (HTB-138) and U-373MG (HTB-17) were cultured in DMEM containing 4.5 g l −1 glucose (DMEM) supplemented with 10% FCS (Biochrom #S0115) and a 1% penicillin and streptomycin mix. For all cells transduced with Tet (tetracycline)-inducible vectors, doxycycline-free serum (Clonetech) was used. Cell lines were authenticated by short tandem repeat analysis. Glioblastoma stem-like (NCH421k) cells were established at the Division of Experimental Neurosurgery, University of Heidelberg, Germany. They were characterized genotypically and phenotypically in a previous study 61 . NCH421k cells were grown as floating aggregates (neurospheres) on uncoated tissue culture dishes in DMEM and F-12 medium containing 20% BIT serum-free supplement, basic fibroblast growth factor and epidermal growth factor at a concentration of 20 ng ml −1 each (all from Provitro). HEK293T and HEK293 cells were maintained as monolayer cultures in DMEM containing 10% FCS without antibiotics. IHAs expressing wild-type IDH1 or R132H mutant IDH1 were provided by T.A.C. and prepared as previously described 62 . They were cultured in DMEM supplemented with 10% FCS, 0.5 µg ml −1 G418 and 1% penicillin and streptomycin mix.
All cell lines were cultivated at 37 °C in a humidified incubator with 5% CO 2 . For hypoxia experiments, cells were cultured at 1% O 2 in a nitrogen-supplied C16 hypoxia incubator for 24 h (Labotect).
Cloning of lentiviral vectors.
To generate inducible shRNA-expressing lentiviral constructs, double-stranded oligonucleotides encoding the desired shRNAs were cloned into the single vector-inducible shRNA construct pLKO-Tet-On using the AgeI and EcoRI restriction sites. Briefly, reconstituted sense and antisense oligonucleotides were mixed with 10× Oligo Annealing Buffer (Invitrogen), incubated at 95 °C for 4 min and left in the turned off heat block overnight. Double-stranded oligonucleotides (0.1 nmol µl −1 ) were cloned into the predigested and purified pLKO-Tet-On vector using the Roche Rapid Ligation Kit following the manufacturer's instructions. The sense and antisense oligonucleotide sequences are given in Supplementary Table 5 .
For overexpression of BCAT1, the insert was generated using PCR with the primers shown in Supplementary Table 5 and subsequently cloned into the XbaI and XhoI sites of the pLVX-puro lentiviral vector (Clontech).
Virus production and transduction. Lentiviral particles were produced by cotransfection of HEK293T cells with the psPAX2 (Addgene 12260, Didier Trono; packaging plasmid), pMD2.G (Addgene 12259, Didier Trono; envelope plasmid) and respective pLKO.1 shRNA constructs (Sigma-Aldrich), inducible pLKO-Tet-On shRNA constructs or the pLVX-puro overexpression vector (Clontech). Transfections were carried out using TransIT-LT1 (Mirus Bio LLC), and viruses was harvested at 48 and 72 h after transfection and combined.
Infection of glioma cells with virus at a multiplicity of infection of 2 was carried out in the presence of 8 µg ml −1 of polybrene (Chemicon). Viruscontaining supernatant was removed after 24 h, and cells were split 3 d, 5 d and 7 d after transduction.
Two shRNA constructs (TRCN0000005907 and TRCN0000005909) targeting different regions of human BCAT1 and two shRNA constructs (TRCN0000027298 and TRCN0000027289) targeting different regions of human IDH1 mRNA transcripts were used. Nontargeting shRNA (Mission SHC002) was used as control.
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Inducible BCAT1 knockdown cells were established by infecting U-87MG and U-373MG cells with pLKO-Tet-On nontargeting shRNA and pLKOTet-On BCAT1 shRNAI lentiviral particles, respectively, and selecting with puromycin (1 µg ml −1 ) for 7 d. Induction was achieved by adding 2 µg ml −1 doxycycline to the medium for at least 5 d. This inducible lentiviral system was previously described 63 .
Quantification of knockdown or overexpression was assessed by qRT-PCR and western blot analysis.
Treatment with dimethyl-a-KG and gabapentin. Fifty thousand cells per well were seeded in 24-well plates in a total volume of 500 µl cell culture medium. The medium was removed 16 h after seeding the cells and replaced with 500 µl medium containing 1 mM, 5 mM or 10 mM dimethyl-α-KG (dimethyl 2-oxoglutarate; Sigma-Aldrich) or 5 mM, 10 mM or 20 mM gabapentin (1-(aminomethyl)-cyclohexane; Sigma-Aldrich). Corresponding volumes of 200 mM HEPES buffer (pH 7.4) were added to the respective control wells.
Cell cycle analysis and detection of apoptosis. Cell cycle analysis was performed 20 h after treatment with gabapentin and 6 d after lentiviral transduction. Nicoletti buffer (0.1% sodium citrate, pH 7.4, 0.05% Triton X-100 and 50 µg ml −1 propidium iodide) was added to the wells containing both dead and living cells. After 4 h in the dark at 4 °C, DNA content was analyzed by flow cytometry using a FACS Canto II (BD Biosciences). FACS Diva software was used to quantify the distribution of cells in each cell cycle phase: sub-G1 (dead cells), G1, S and G2/M.
For investigation of apoptotic activity after BCAT1 lentiviral knockdown, NCH421k cells were incubated with annexin V-phycoerythrin (PE) and 7-AAD (BD Biosciences) for 15 min in the dark, which was immediately followed by flow cytometry.
Proliferation analysis.
To assess the proliferation of glioma cells after treatment with gabapentin or after lentiviral knockdown, the Click-iT EdU cell proliferation assay (Invitrogen) was used following the manufacturer's instructions. The cells were incubated with 10 µM of the nucleoside analog EdU for 10-16 h. Quantification of cells that incorporated EdU was performed using a FACS Canto II (BD Biosciences).
Synchronization of cells by double thymidine block. U-87MG cells were synchronized at the G1/S boundary by culturing them in the presence of 2 mM thymidine (Sigma-Aldrich) in DMEM plus 10% FCS for 16 h. They were washed with PBS and allowed to recover in complete growth medium that lacked thymidine for 11 h and then propagated again in 2 mM thymidine for an additional 14 h.
Glutamate quantification. Glutamate concentration in the supernatants of cells was determined using the Glutamine and Glutamate Determination Kit (GLN-1, Sigma-Aldrich) according to the manufacturer's instructions. The reaction volumes were scaled down to 100 µl total volume, and absorbance was measured in triplicate in a microplate (Corning 96 Well Clear Flat Bottom UV-Transparent Microplate) using a Tecan Infinite M200 plate reader (Tecan). The data were normalized to the number of cells per well.
Immunofluorescence staining. Cells were plated on glass coverslips 5 d after lentiviral transduction. Cells were fixed in 4% formaldehyde, rinsed twice in PBS and permeabilized in PBS containing 0.2% Triton X-100. After rinsing with PBS, cells were incubated in 10% goat serum for 30 min at room temperature. Samples were incubated for 1 h with the primary antibody (mouse antibody to α-tubulin, 1:200, clone DM1A, #T9026, Sigma-Aldrich) and for 1 h at room temperature with the secondary antibody (FITC-conjugated goat mouse-specific antibody, 1:100, ab6785, Abcam) after mounting with DAPIcontaining Vectashield mounting medium (Vector Laboratories). For fluorescence imaging, images were taken using a ×40 objective lens on a Zeiss Axioplan microscope.
Three-dimensional microchannel migration assay. For migration assays, we used poly(dimethylsiloxane) (PDMS)-based microchannel chips (provided by R. Kemkemer). Microfabricated channel structures with the dimensions 5 µm × 11 µm × 300 µm (width × height × length) were biofunctionalized by incubation with a 50 µg ml −1 fibronectin solution before use. The chip was fixed on a Teflon holder, and 2 × 10 5 cells were seeded on the chip in close proximity to the channels. After cells were attached on the chip, live-cell imaging was performed for 25 h. During the experiments, no chemical gradient or flow inside the channels was applied. Phase-contrast time-lapse pictures of multiple positions were captured every 10 min with an automated inverted microscope (Zeiss Cell Observer, Carl Zeiss) equipped with an air-humidified and heated chamber. Images were recorded and processed with Zeiss AxioVision and ImageJ software. Cell behaviors were analyzed and categorized as reported previously 64, 65 .
Animal experiments. Animal work for the orthotopic brain tumor model was approved by the governmental authorities (Regierungspraesidium Karlsruhe, Germany) and supervised by institutional animal protection officials in accordance with the US National Institutes of Health guidelines Guide for the Care and Use of Laboratory Animals. Protocols for animal use for the 2-HG inhibition studies were approved by the Animal Care Use Committee of Virginia Polytechnic Institute in accordance with the US National Institutes of Health guidelines. Orthotopic brain tumor model. A total of 2 × 10 5 U-87MG cells with BCAT1 shRNAI knockdown or nontargeting shRNA were stereotactically implanted into the brains of six female 7-to 9-week-old athymic mice (CD-1 nu/nu; Charles River Laboratories). Four weeks after implantation, mice were euthanized, and their brains were removed and cryosectioned. Brain sections were stained with H&E, and tumor volume was calculated using ImageJ.
Inducible orthotopic brain tumor model. Two-hundred thousand U-87MG cells stably transduced with inducible pLKO-Tet-On-BCAT1 shRNAI were stereotactically implanted into the brains of 12 female 7-to 9-week-old CD-1 nu/nu mice. Ten days after cranial implantation, six mice received water containing 2 mg ml −1 doxycycline and 1.25% sucrose, and six mice were fed with water containing 1.25% sucrose only. After MRI at 18 and 25 d after implantation, mice were euthanized, and their brains were removed and cryosectioned, or tumor cells were isolated for quantification of glutamate release.
MRI. MRI scans were performed using a custom-developed transmit and receive small-animal coil in a conventional whole-body 1.5 T MRI scanner (Symphony, Siemens). T1-weighted imaging was performed using a high-resolution spin echo sequence (echo delay time, 600 ms; repetition time, 14 ms; field of view, 40 mm × 40 mm; matrix, 192; voxel size, 0.2 × 0.2 × 1 mm 3 ) 5 min after intraperitoneal administration of 80 µl gadopentetic acid (Gd-DTPA) contrast agent (0.5 mmol ml −1 ; Magnevist, Bayer Schering Pharma).
Isolation of cells from xenograft tumors. After mice were euthanized, resected tumor pieces were immediately stored in sterile, cold PBS. Tumor pieces were washed thoroughly and minced in cold PBS. Tissue pieces were incubated in 1 ml trypsin at 37 °C and suspended in DMEM supplemented with 10% FCS and a 1% penicillin and streptomycin mix after 10 min. After collecting the pieces by centrifugation, this step was repeated twice, followed by seeding of cells into six-well plates. After 10 h of incubation at 37 °C, DMEM containing 2 µg ml −1 puromycin was added to eliminate contaminating mouse tissue.
TUNEL staining of brain sections. Fluorescent TUNEL staining was performed using the In situ Cell Death Detection Kit (Roche Diagnostic GmbH) according to the manufacturer's instructions. Frozen brain sections were fixed in 4% paraformaldehyde for 20 min at room temperature, rinsed three times in PBS and permeabilized in 0.1% citrate buffer (pH 6.0) containing 0.1% Triton X-100 for 2 min on ice. After washing in PBS, the sections were incubated with a mixture of terminal deoxynucleotidyl transferase (TdT) enzyme solution and FITC-labeled deoxyuridine triphosphate (dUTP) solution in a humidified chamber in the dark at 37 °C for 60 min. After washing, the slides were mounted with DAPI-containing Vectashield mounting medium (Vector Laboratories). Slides were examined with a Zeiss Axioplan microscope, and images were taken using a ×40 objective lens. Negative controls were obtained by replacing the TdT solution with distilled npg
